Consultant Dermatologist
is a consultant dermatologist treating both adults and children with a wide range of skin conditions.
Her NHS practice is at St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust. She holds an Honorary Chair of Paediatric Dermatology at King’s College London.
Professor Mellerio consults privately at
ABOUT
Jemima completed her medical training at the London Hospital Medical College in Whitechapel where she also gained a first class BSc in Physiology. After completing her postgraduate medical training in North and East London, she undertook her specialist dermatology training at St John’s Institute of Dermatology and King’s College Hospital, London, joining the Specialist Register for Dermatology in 2002.
In 2003 Jemima was appointed as a Consultant at St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust, working in general adult and paediatric dermatology, with subspecialty clinics in adult epidermolysis bullosa (EB) and other genetic skin diseases. Between 2003 and 2017, she was the dermatologist for the Paediatric EB Service at Great Ormond Street Hospital for Children NHS Foundation Trust. At St John’s she has been the Lead for the Adult EB Service since 2003, Lead for Paediatric and Genetic Dermatology from 2006 until 2018 and Chief of Dermatology from 2018 to 2023.
Jemima treats a range of dermatological problems in adults and children including acne, eczema, psoriasis, rosacea, vitiligo, birthmarks and hair disorders, as well as undertaking mole checks and treating sun damage and skin cancers. She is an international expert in the diagnosis and management of genetic skin diseases including EB, ichthyosis, ectodermal dysplasia and other related disorders.
Undertaking an MD higher degree at St John’s in the genetics and clinical features of EB gave Jemima a firm scientific footing on which she has built a successful research career in genetic skin diseases and paediatric dermatology. She has over 150 peer-reviewed publications, has authored many chapters in pre-eminent textbooks of dermatology and also lectures both nationally and worldwide in her areas of expertise. Her current research interests include translational therapies for genetic skin diseases and she is chief investigator on a long-term prospective project exploring the natural history of recessive dystrophic EB.
Jemima’s approach to her patients is one of empathy and listening, combining her clinical expertise with her scientific knowledge to provide holistic, patient-centred and evidence-based care.
Prof Jemima Mellerio is recognised by all major private health insurers. She is a Fellow of the Royal College of Physicians, a member of the British Association of Dermatologists and is on the Executive Committees of the Royal Society of Medicine Section of Dermatology (Section President 2018/19) and the British Society of Paediatric Dermatology and the International Society of Pediatric Dermatology. She is South London Representative on the Executive Committee of the British Association of Dermatologists and is Honorary Treasurer of the British Society of Paediatric and Adolescent Dermatology.
Professor Jemima Mellerio offers face to face and virtual consultations at
One Welbeck Skin Health and Allergy
1 Welbeck Street
Marylebone
London W1G 0AR
+44 (0)203 653 2000
Alternatively book a consultation here or email/call her secretary Eleanor
+44 (0)203 985 1275
TESTIMONIALS
PUBLICATIONS
Prof Jemima Mellerio has authored over 190 peer-reviewed publications.
She has also written chapters for leading dermatology textbooks including Rook’s Textbook of Dermatology, Bolognia’s Dermatology, Haprer’s Textbook of Paediatric Dermatology
and Schachner and Hansen’s Pediatric Dermatology.
Here is a selection.
Itch in recessive dystrophic epidermolysis bullosa: findings of PEBLES, a prospective register study. Mellerio JE, Pillay EI, Ledwaba-Chapman L, Bisquera A, Robertson SJ, Papanikolaou M, McGrath JA, Wang Y, Martinez AE, Jeffs E. Orphanet J Rare Dis. 2023; 18: 235.
Mapping the burden of severe forms of epidermolysis bullosa – implications for patient management. Mellerio JE, Kiritsi D, Marinkovich MP, Haro NR, Badger K, Arora M, Dziasko MA, Vithlani M, Martinez AE. JAAD Int. 2023; 11: 224-32.
Treatment of multifactorial anaemia in adults with severe epidermolysis bullosa using intravenous ferric carboxymaltose; a single institution, observational, retrospective study. Alheggi A, McGrath JA, Hubbard L, Greenblatt DT, Mellerio JE. Br J Dermatol. 2023; 188: 306-7.
Understanding the socioeconomic costs of dystrophic epidermolysis bullosa in Europe: a costing and health-related quality of life study. Angelis A, Mellerio JE, Kanavos P. Orphanet J Rare Dis. 2022; 17: 346.
The epidemiology of epidermolysis bullosa in England and Wales: data from the national epidermolysis bullosa database. Petrof G, Papanikolaou M, Martinez AE, Mellerio JE, McGrath JA, Bardhan A, Harper N, Heagerty A, Ogboli M, Chiswell C, Moss C. Br J Dermatol. 2022; 186: 843-8.
Recommendations on pregnancy, childbirth and aftercare in epidermolysis bullosa: a consensus-based guideline. Greenblatt DT, Pillay E, Snelson K, Saad R, Torres Pradilla M, Widhiati S, Diem A, Knight C, Thompson K, Azzopardi N, Wekentoft M, Moore Z, Patton D, Mayre-Chilton KM, Murrell DF, Mellerio JE. Br J Dermatol. 2022; 186: 620-32.
Heterogeneous addiction to TGFβ signalling in recessive dystrophic epidermolysis bullosa associated cutaneous squamous cell carcinoma. Dayal JHS, Mason SM, Salas-Alanis JC, McGrath JA, Taylor RG, Mellerio JE, Blyth K, South AP, Inman GJ. Br J Dermatol. 2021; 184: 697-708
Prevalence, pathophysiology and management of itch in epidermolysis bullosa. Papanikolaou M, Onoufriadis A, Mellerio JE, Nattkemper L, Yosipovitch G, Steinhoff M, McGrath JA. Br J Dermatol. 2021; 184:816-25
Cutaneous squamous cell carcinoma in epidermolysis bullosa: a 28-year retrospective study. Robertson SJ, Orrin E, Lakhan MK, O’Sullivan G, Felton J, Robson A, Greenblatt DT, Bernardis C, McGrath JA, Martinez AE, Mellerio JE. Acta Derm Venereol. 2021; 101: adv00523.
Epidermolysis bullosa. Bardhan A, Bruckner-Tuderman L, Chapple ILC, Fine JD, Harper N, Has C, Magin TM, Marinkovich MP, Marshall JF, McGrath JA, Mellerio JE, Polson R, Heagerty AH. Nat Rev Dis Primers. 2020; 6: 78.
Consensus re-classification of inherited epidermolysis bullosa and other disorders with skin fragility. Has C, Bauer JW, Bodemer C, Bolling M, Bruckner-Tuderman L, Diem A, Fine JD, Heagerty A, Hovnanian A, Marinkovich P, Martinez AE, McGrath JA, Moss C, Murrell DF, Palisson F, Schwieger-Briel A, Sprecher E, Tamai K, Uitto J, Woodley DT, Zambruno G, Mellerio JE. Br J Dermatol. 2020; 183: 614-27.
Homozygous nonsense mutation in DSC3 resulting in skin fragility and hypotrichosis. Onoufriadis A, Ahmed N, Bessar H, Guy A, Liu L, Marantzidis A, Kesidou E, Papanikolaou M, Simpson MA, Mellerio JE, Lee JYW, McGrath JA. J Invest Dermatol. 2020; 140: 1285-8.
Phase I/II open-label trial of intravenous allogeneic mesenchymal stromal cell therapy in adults with recessive dystrophic epidermolysis bullosa. Rashidghamat E, Kadiyirire T, Ayis S, Petrof G, Liu L, Pullabhatla V, Ainali C, Guy A, Aristodemou S, McMillan JR, Ozoemena L, Mee J, Prmanik R, Saxena A, Nuamah R, de Rinaldis E, Serrano S, Maurin C, Martinez-Queipo M, Lwin SM, Ilic D, Martinez A, Dazzi F, Slaper-Cortenbach I, Westinga K, Zeddies S, van den Broek M, Onoufriadis A, Mellerio JE, McGrath JA. J Am Acad Dermatol. 2020; 83: 447-54.
Genotype-phenotype correlation in a large English cohort of autosomal recessive ichthyosis. Simpson JK, Martinez-Quiepo M, Onoufriadis A, Tso S, Glass E, Liu L, Higashino T, Scott W, Tierney C, Simpson MA, Desomchoke R, Youssefian L, Saeldian AH, Vahidnezhad H, Bisquera A, Goldstraw N, Cork MJ, Darne S, Uitto J, Martinez AE, Mellerio JE, McGrath JA. Br J Dermatol. 2020; 182: 729-37.
Generation and clinical application of gene-modified autologous epidermal sheets in Netherton syndrome: lessons learned from a phase 1 trial. Di WL, Lwin SM, Petrova A, Bernardis C, Syed F, Farzaneh F, Moulding D, Martinez AE, Sebire NJ, Rampling D, Virasami A, Zamirir M, Wang W, Hara H, Kadiyirire T, Abdul-Wahab A, Martinez-Quiepo M, Harper JI, McGrath JA, Thrasher AJ, Mellerio JE, Qasim W. Hum Gene Ther 2019; 30: 1067-78.
Safety and early efficacy outcomes for lentiviral fibroblast gene therapy in recessive dystrophic epidermolysis bullosa. Lwin SM, Syed F, Di W-L, Kadiyirire T, Liu L, Guy A, Petrova A, Abdul-Wahab A, Reid F, Phillips R, Elstad M, Georgiadis C, Aristodemou S, Lovell PA, McMillan JR, Mee J, Miskinyte S, Titeux M, Ozoemena L, Pramanik R, Serrano S, Rowles R, Maurin C, Orrin E, Martinez-Quiepo M, Rashidghamat E, Tziotzios C, Onoufriadis A, Chen M, Chan L, Farzaneh F, Del Rio M, Tolar J, Bauer JW, Larcher F, Antoniou MN, Hovnanian A, Thrasher AJ, Mellerio JE, Qasim W, McGrath JA. JCI Insight 2019; 4: 126243.
Identification of rigosertib for the treatment of recessive dystrophic epidermolysis bullosa-associated squamous cell carcinoma. Atanasova VA, Pourreyon C, Farshchian M, Lawler M, Brown CA 4th, Watt SA, Wright S, Warkala M, Guttmann-Gruber C, Hofbauer JP, Fuentes I, Prisco M, Rashidghamat E, Has C, Salas-Alanis JC, Palisson F, Hovnanian A, McGrath JA, Mellerio JE, Bauer JW, South AP. Clin Cancer Res. 2019; 25: 3384-91.
Mutations in KLHL24 add to the molecular heterogeneity of epidermolysis bullosa simplex. Lee JY, Liu L, Hsu CK, Aristodemou S, Ozoemena L, Ogboli M, Moss C, Martinez AE, Mellerio JE, McGrath JA. J Invest Dermatol 2017; 137: 1378-80.
The p.Glu477Lys mutation in keratin 5 is strongly associated with mortality in generalized severe epidermolysis bullosa simplex. Sathishkumar D, Orrin E, Terron-Kwitkowski A, Browne F, Martinez AE, Mellerio JE, Ogboli M, Hoey S, Ozoemena L, Liu L, Baty D, McGrath JA, Moss C. J Invest Dermatol 2016; 136: 719-21.
Management of cutaneous squamous cell carcinoma in patients with epidermolysis bullosa – best clinical practice guidelines. Mellerio JE, Robertson SJ, Bernardis C, Diem A, Fine JD, George R, Goldberg D, Halmos GB, Harries M, Jonkman MF, Lucky A, Martinez AE, Maubec E, Morris S, Murrell DF, Palisson F, Pillay EI, Robson A, Salas-Alanis JC, McGrath JA. Br J Dermatol 2016; 174: 56-67.
Potential of systemic allogeneic mesenchymal stromal cell therapy for children with recessive dystrophic epidermolysis bullosa. Petrof G, Lwin SM, Martinez-Quiepo M, Abdul-Wahab A, Tso S, Mellerio JE, Slaper-Cortenbach I, Boelens JJ, Tolar J, Veys P, Ofuya M, Peacock JL, Martinez AE, McGrath JA. J Invest Dermatol 2015; 135: 2319-21.
Phase I study protocol for ex-vivo lentiviral gene therapy for the treatment of the inherited skin disease, Netherton Syndrome. Di WL, Mellerio JE, Bernardis C, Harper J, Abdul-Wahab A, Ghani S, Martinez-Queipo M, Hara H, McNicol AM, McGrath J, Thrasher AJ, Qasim W. Hum Gene Ther Clin Dev 2013; 24: 182-90.
Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: results of a randomised, vehicle-controlled trial. Petrof G, Martinez-Queipo M, Mellerio JE, Kemp P, McGrath JA. Br J Dermatol 2013; 169: 1025-33.
Germline mutation in EXPH5 implicates the Rab27B effector protein Slac2-b in inherited skin fragility. McGrath JA, Stone KL, Begum R, Simpson MA, Dopping-Hepenstal PJ, McMillan JR, South AP, Pourreyron C, McLean WH, Martinez AE, Mellerio JE, Parsons M. Am J Hum Genet 2012; 91: 1115-21.
Extracutaneous manifestations and complications of inherited epidermolysis bullosa. Part I. Epithelial associated tissues. Fine J-D, Mellerio JE. J Am Acad Dermatol 2009; 61: 367-84.
Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. Wong T, Gammon L, Liu L, Mellerio JE, Dopping-Hepenstal PJ, Pacy J, Elia G, Jeffery R, Leigh IM, Navsaria H, McGrath JA. J Invest Dermatol 2008; 128: 2179-89.
An unusual N-terminal deletion of the laminin alpha3a isoform leads to the chronic granulation tissue disorder laryngo-onycho-cutaneous syndrome. McLean WH, Irvine AD, Hamill KJ, Whittock NV, Coleman-Campbell CM, Mellerio JE, Ashton GHS, Dopping-Hepenstal PJ, Eady RAJ, Jamil T, Phillips RJ, Shabbir SG, Haroon TS, Khurshid K, Moore JE, Page B, Darling J, Atherton DJ, Van Steensel MA, Munro CS, Smith FJ, McGrath JA. Hum Mol Genet 2003; 12: 2395-409.
Lipoid proteinosis maps to 1q21 and is caused by mutations in the extracellular matrix protein 1 gene (ECM1). Hamada T, McLean WHI, Ramsay M, Ashton GHS, Nanda A, Jenkins T, Edelstein I, South AP, Bleck O, Wessagowit V, Mallipeddi R, Orchard GE, Wan H, Dopping-Hepenstal PJC, Mellerio JE, Whittock NV, Munro CS, van Steensel MAN, Steijlen PM, Ni J, Zhang L, Hashimoto T, Eady RAJ, McGrath JA. Hum Mol Genet 2002; 11: 833-40.
Allelic heterogeneity of dominant and recessive COL7A1 mutations underlying epidermolysis bullosa pruriginosa. Mellerio JE, Ashton GHS, Mohammedi R, Lyon CC, Kirby B, Harman KE, Salas-Alanis JC, Atherton DJ, Harrison PV, Griffiths WAD, Black MM, Eady RAJ, McGrath JA. J Invest Dermatol 1999; 112: 984-7.
Pyloric atresia-junctional epidermolysis bullosa syndrome: mutations in the integrin β4 gene (ITGB4) in two unrelated cases with mild disease. Mellerio JE, Pulkkinen L, McMillan JR, Lake BD, Horn HM, Tidman MJ, Harper JI, McGrath JA, Uitto J, Eady RAJ. Br J Dermatol 1998; 139: 862-71.
Recessive epidermolysis bullosa simplex associated with plectin mutations: infantile respiratory complications in two unrelated cases. Mellerio JE, Smith FJD, McMillan JR, McLean WHI, McGrath JA, Morrison GAJ, Tierney P, Albert DM, Wiche G, Leigh IM, Geddes JF, Lane EB, Uitto J, Eady RAJ. Br J Dermatol 1997; 137: 898-906.
LECTURES
Prof Jemima Mellerio gives talks and lectures worldwide.
Here is a selection of her most recent.